P394: Prolonged azathioprine treatment reduces the need for surgery in early Crohn's diseaseECCO '17 Barcelona
2017
P396: Long-term efficacy of thiopurines as maintenance treatment in 130 patients with ulcerative colitisECCO '17 Barcelona
2017
P397: Approach and management of psychological aspects of inflammatory bowel disease described by patients and physicians in Spain. The ENMENTE ProjectECCO '17 Barcelona
2017
P398: An objective measure of response to treatment for patients with Crohn's perianal fistulas on anti-TNF treatmentECCO '17 Barcelona
2017
P399: Adverse events associated with azathioprine treatment in Korean pediatric inflammatory bowel disease patientsECCO '17 Barcelona
2017
P400: Risk-adjusted use of thiopurines prevented surgical recurrence in patients with Crohn's disease after intestinal resectionECCO '17 Barcelona
2017
P401: Anti-TNF treatments in Crohn's disease and improvement in work productivity and quality of life: an observational study from TurkeyECCO '17 Barcelona
2017
P402: Discontinuation of short-term infliximab maintenance therapy in patients with Crohn's disease: outcomes and risk factors associated with relapseECCO '17 Barcelona
2017
P403: Golimumab therapy for ulcerative colitis – an Irish multicentre experienceECCO '17 Barcelona
2017
P404: Vaccinations and immunization status in Paediatric inflammatory bowel disease: data from the VIP IBD studyECCO '17 Barcelona
2017
P405: Toxicity of thiopurines in patients with inflammatory bowel disease: inventory and predictive factorsECCO '17 Barcelona
2017
P406: Clinical correlations of infliximab trough levels and antibodies to infliximab in Korean patients with Crohn's diseaseECCO '17 Barcelona
2017
P407: Prospective evaluation of clinical efficacy and safety of golimumab in biologic experienced and naïve patients with moderate to severe ulcerative colitis: experience from a tertiary referral centreECCO '17 Barcelona
2017
P408: Long-term efficacy of infliximab in patients with ulcerative colitis – an observational study from a single center in NorwayECCO '17 Barcelona
2017
P409: Mesalamine enemas for induction of remission in pediatric ulcerative colitis refractory to oral mesalamine: a prospective cohort studyECCO '17 Barcelona
2017
P410: Vedolizumab is safe and effective for IBD, but has no effect on liver biochemistry in patients with concurrent PSCECCO '17 Barcelona
2017
P411: Drug persistence and need for dose intensification to adalimumab therapy; the importance of therapeutic drug monitoring in inflammatory bowel diseasesECCO '17 Barcelona
2017